BCR and chronic myelogenous leukemia, BCR-ABL1 positive: This latter hypothesis is consistent with the observation of BCR-ABL-positive hematopoietic cells also in healthy individuals [35], but is challenged by the observation that a fraction of CML patients who have achieved a sustained complete molecular remission (CMR) on imatinib can remain in CMR after drug withdrawal [36].